Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “buy” rating reaffirmed by stock analysts at Wedbush in a research report issued on Tuesday, AnalystRatings.com reports. They presently have a $186.00 target price on the biotechnology company’s stock. Wedbush’s price target would suggest a potential upside of 58.16% from the company’s previous close.
ASND has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating and set a $118.00 target price on the stock in a report on Tuesday, October 29th. Morgan Stanley initiated coverage on shares of Ascendis Pharma A/S in a research report on Friday, October 11th. They set an “overweight” rating and a $128.00 price target for the company. ValuEngine raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. BidaskClub lowered shares of Ascendis Pharma A/S from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 12th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Ascendis Pharma A/S from $143.00 to $152.00 and gave the stock an “overweight” rating in a report on Thursday, August 29th. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $142.75.
ASND opened at $117.60 on Tuesday. The company has a quick ratio of 11.59, a current ratio of 11.59 and a debt-to-equity ratio of 0.05. Ascendis Pharma A/S has a 52 week low of $54.67 and a 52 week high of $133.96. The stock has a market cap of $4.74 billion, a PE ratio of -31.44 and a beta of 0.63. The business has a 50 day moving average of $104.50 and a 200-day moving average of $113.04.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ASND. Henry James International Management Inc. increased its holdings in shares of Ascendis Pharma A/S by 139.7% during the second quarter. Henry James International Management Inc. now owns 8,407 shares of the biotechnology company’s stock valued at $968,000 after acquiring an additional 4,900 shares in the last quarter. JGP Global Gestao de Recursos Ltda. bought a new stake in Ascendis Pharma A/S during the 2nd quarter valued at about $343,000. SG Americas Securities LLC raised its holdings in Ascendis Pharma A/S by 523.9% in the second quarter. SG Americas Securities LLC now owns 13,027 shares of the biotechnology company’s stock worth $1,500,000 after buying an additional 10,939 shares during the last quarter. First Trust Advisors LP purchased a new position in Ascendis Pharma A/S in the second quarter worth about $215,000. Finally, Aperio Group LLC lifted its stake in shares of Ascendis Pharma A/S by 3.3% in the second quarter. Aperio Group LLC now owns 4,582 shares of the biotechnology company’s stock worth $528,000 after buying an additional 147 shares in the last quarter.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Further Reading: What is diluted earnings per share (Diluted EPS)?
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.